Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:JAZZ NASDAQ:MRTX NASDAQ:MRVI NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.18-0.6%$48.97$21.72▼$54.60$9.84B1.252.10 million shs1.81 million shsJAZZJazz Pharmaceuticals$129.54+2.4%$119.65$95.49▼$148.06$7.68B0.24667,460 shs775,697 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AMRVIMaravai LifeSciences$2.81-2.8%$2.50$1.66▼$9.50$738M0.29913,382 shs1.61 million shsUTHRUnited Therapeutics$403.68+1.4%$324.92$266.98▼$436.95$17.95B0.62864,304 shs581,400 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.60%-3.36%+4.41%+27.95%+91.47%JAZZJazz Pharmaceuticals+2.37%+2.08%+10.09%+19.68%+16.13%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%MRVIMaravai LifeSciences-2.77%+8.08%+9.34%+39.80%-69.59%UTHRUnited Therapeutics+1.43%+1.81%+28.52%+38.38%+17.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.18-0.6%$48.97$21.72▼$54.60$9.84B1.252.10 million shs1.81 million shsJAZZJazz Pharmaceuticals$129.54+2.4%$119.65$95.49▼$148.06$7.68B0.24667,460 shs775,697 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AMRVIMaravai LifeSciences$2.81-2.8%$2.50$1.66▼$9.50$738M0.29913,382 shs1.61 million shsUTHRUnited Therapeutics$403.68+1.4%$324.92$266.98▼$436.95$17.95B0.62864,304 shs581,400 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.60%-3.36%+4.41%+27.95%+91.47%JAZZJazz Pharmaceuticals+2.37%+2.08%+10.09%+19.68%+16.13%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%MRVIMaravai LifeSciences-2.77%+8.08%+9.34%+39.80%-69.59%UTHRUnited Therapeutics+1.43%+1.81%+28.52%+38.38%+17.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.93% UpsideJAZZJazz Pharmaceuticals 2.88Moderate Buy$178.6737.92% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/AMRVIMaravai LifeSciences 2.18Hold$5.2285.72% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$438.858.71% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, MRVI, JAZZ, BBIO, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.009/4/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$415.00 ➝ $560.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.009/3/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$295.00 ➝ $414.009/2/2025UTHRUnited TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$432.00 ➝ $564.009/2/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$314.00 ➝ $463.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M44.09N/AN/A($7.71) per share-6.64JAZZJazz Pharmaceuticals$4.09B1.92$31.06 per share4.17$67.72 per share1.91MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39MRVIMaravai LifeSciences$259.18M2.77$0.60 per share4.68$2.28 per share1.23UTHRUnited Therapeutics$2.88B6.33$28.79 per share14.02$144.34 per share2.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A6.927.85-9.91%5.02%1.73%11/5/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AMRVIMaravai LifeSciences-$144.85M-$1.36N/AN/AN/A-90.03%-17.60%-9.30%11/6/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6215.7614.686.0740.36%18.73%16.49%10/29/2025 (Estimated)Latest UTHR, MRVI, JAZZ, BBIO, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billion7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08JAZZJazz Pharmaceuticals1.171.621.37MRTXMirati TherapeuticsN/A7.547.40MRVIMaravai LifeSciences0.685.164.49UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%JAZZJazz Pharmaceuticals89.14%MRTXMirati TherapeuticsN/AMRVIMaravai LifeSciences50.25%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%JAZZJazz Pharmaceuticals4.30%MRTXMirati Therapeutics3.26%MRVIMaravai LifeSciences2.11%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableMRVIMaravai LifeSciences610255.36 million249.97 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, MRVI, JAZZ, BBIO, and MRTX HeadlinesRecent News About These CompaniesBalefire LLC Invests $376,000 in United Therapeutics Corporation $UTHR3 hours ago | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Trims Holdings in United Therapeutics Corporation $UTHR3 hours ago | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 SharesSeptember 17 at 8:27 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of StockSeptember 17 at 5:46 AM | insidertrades.comVoya Investment Management LLC Boosts Stock Position in United Therapeutics Corporation $UTHRSeptember 17 at 3:44 AM | marketbeat.comUnited Therapeutics management to meet with Cantor FitzgeraldSeptember 16 at 8:23 PM | msn.comLiquidia Corporation (LQDA): A Bull Case TheorySeptember 16 at 3:22 PM | uk.finance.yahoo.comUnited Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare ForumSeptember 16 at 10:19 AM | pharmiweb.comPSwedbank AB Decreases Stock Position in United Therapeutics Corporation $UTHRSeptember 15 at 5:27 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLCSeptember 15 at 3:30 AM | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 25,289 Shares of United Therapeutics Corporation $UTHRSeptember 15 at 3:09 AM | marketbeat.comFY2025 EPS Estimates for UTHR Raised by Cantor FitzgeraldSeptember 14, 2025 | marketbeat.comInspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHRSeptember 14, 2025 | marketbeat.comUTHR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 14, 2025 | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in StockSeptember 13, 2025 | marketbeat.comFY2026 EPS Estimates for UTHR Increased by Cantor FitzgeraldSeptember 13, 2025 | marketbeat.comAcadian Asset Management LLC Acquires 169,010 Shares of United Therapeutics Corporation $UTHRSeptember 13, 2025 | marketbeat.comFred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHRSeptember 13, 2025 | marketbeat.comEquities Analysts Offer Predictions for UTHR FY2026 EarningsSeptember 13, 2025 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in StockSeptember 12, 2025 | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of StockSeptember 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, MRVI, JAZZ, BBIO, and MRTX Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.18 -0.31 (-0.60%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$51.30 +0.12 (+0.22%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Jazz Pharmaceuticals NASDAQ:JAZZ$129.54 +3.00 (+2.37%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$129.88 +0.34 (+0.26%) As of 06:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Maravai LifeSciences NASDAQ:MRVI$2.81 -0.08 (-2.77%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.81 0.00 (0.00%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$403.68 +5.71 (+1.43%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$403.51 -0.17 (-0.04%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
